<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>form8k801ex992dec-17.txt
<DESCRIPTION>EXHIBIT 99.2
<TEXT>




                                  EXHIBIT 99.2




<PAGE>


8229 Boone Boulevard, Suite 802                              COMPANY CONTACT:
Vienna, VA  22182.  placecountry-regionUSA                   Gavin de Windt
Telephone (703) 506-9460                                     CEL-SCI Corporation
www.cel-sci.com                                              (703) 506-9460

  CEL-SCI REACHES FULL ENROLLMENT IN PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

 Major Milestone Achieved in World's Largest Head and Neck Cancer Phase 3 Study

VIENNA,  VA,  December  11, 2017 -- CEL-SCI  Corporation  (NYSE  American:  CVM)
announced  today that no further  patient  enrollment is required in the pivotal
Phase  3  head  and  neck  cancer  study  of its  investigational  immunotherapy
Multikine* (Leukocyte Interleukin,  Injection). The accrual and treatment phases
of this Phase 3 study are  complete.  All of the 928  enrolled  patients  in the
study are being followed-up as required by the study protocol.

CEL-SCI  recently  announced  that  the  study's   Independent  Data  Monitoring
Committee  (IDMC)  completed  its most  recent  review  of the data from all 928
patients  enrolled in the study,  and recommended  continuing the study as there
was no evidence of any significant safety questions.

The primary  endpoint of the study, a 10% improvement in overall survival of the
Multikine  treatment  regimen plus  Standard of Care (SOC) vs.  Standard of Care
alone, will be determined after a total of 298 deaths have occurred in these two
main  comparator arms of the study and have been recorded in the study database.
The last patient was enrolled in the study in September 2016.  Approximately 135
patients were  enrolled in the study from 2011 to 2013,  about 195 were enrolled
in 2014, about 340 in 2015, and about 260 in 2016. The study protocol assumed an
overall survival rate of about 55% at 3 years for the SOC treatment group alone.

IDMCs are committees commonly used by sponsors of clinical trials to protect the
interests of the patients and the integrity of the study data in ongoing trials,
especially when the trials involve patients with life threatening diseases,  and
when, as in cancer clinical trials, they extend over long periods of time.

About CEL-SCI Corporation

CEL-SCI  is a Phase 3 cancer  immunotherapy  company.  When it  comes to  cancer
immunotherapy, CEL-SCI believes it is most logical to boost the patient's immune
system while it is still intact in order to have the greatest possible impact on
survival.  Therefore,  CEL-SCI treats patients who are newly diagnosed with head
and neck cancer with  Multikine  BEFORE they have  received  surgery,  radiation
and/or chemotherapy.  This approach is unique. Most other cancer immunotherapies

                                       1
<PAGE>

are used only after conventional  therapies have been tried and/or failed.  Head
and neck cancer  represents  about 6% of all  cancers.  Multikine  has  received
Orphan Drug  designation  from the FDA for the treatment of head and neck cancer
patients with advanced squamous cell carcinoma.

The Company's LEAPS  technology is being developed as a therapeutic  vaccine for
rheumatoid  arthritis and is supported by grants from the National Institutes of
Health.  CEL-SCI has patents on  Multikine  from the U.S.,  Europe,  China,  and
Japan.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans" and  "expects,"  and
similar expressions,  are intended to identify forward-looking  statements. Such
statements  are  subject  to risks and  uncertainties  that could  cause  actual
results to differ  materially from those projected.  Factors that could cause or
contribute to such differences  include,  an inability to duplicate the clinical
results  demonstrated in clinical studies,  timely  development of any potential
products  that  can be  shown  to be safe  and  effective,  receiving  necessary
regulatory  approvals,  difficulties  in  manufacturing  any  of  the  Company's
potential  products,  inability  to raise  the  necessary  capital  and the risk
factors set forth from time to time in CEL-SCI's filings with the Securities and
Exchange  Commission,  including  but not limited to its report on Form 10-K and
10-K/A  for the year  ended  September  30,  2016.  The  Company  undertakes  no
obligation   to  publicly   release   the  result  of  any   revision  to  these
forward-looking   statements  which  may  be  made  to  reflect  the  events  or
circumstances   after  the  date  hereof  or  to  reflect  the   occurrence   of
unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has
registered  for  this  investigational  therapy,  and this  proprietary  name is
subject  to FDA  review in  connection  with the  Company's  future  anticipated
regulatory submission for approval.  Multikine has not been licensed or approved
for  sale,  barter  or  exchange  by the  FDA or any  other  regulatory  agency.
Similarly,  its  safety  or  efficacy  has not  been  established  for any  use.
Moreover,  no  definitive   conclusions  can  be  drawn  from  the  early-phase,
clinical-trials  data involving the investigational  therapy Multikine.  Further
research is required,  and early-phase  clinical trial results must be confirmed
in the  Phase 3  clinical  trial  of  this  investigational  therapy  that is in
progress.
</TEXT>
</DOCUMENT>
